RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP

Price 900 INR/ Box

Get a Price/Quote

MOQ : 100 Boxes

RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP Specification

Composition
Rabeprazole 20 mg + Domperidone 30 mg (Sustained Release)

Usage/Application
Used to treat gastroesophageal reflux disease (GERD), acidity, and vomiting.

Strength
Rabeprazole 20mg, Domperidone 30mg

Prescription/Non prescription
Prescription

Release Type
Sustained Release (SR)

Dosage Form
Capsule

Packaging Type
Strip

Indications
Indicated for gastrointestinal disorders including acid reflux, peptic ulcer, and chronic gastritis.

Packaging Size
10x10 capsules

Administration Route
Oral

Shelf Life
24 months

Storage Condition
Store below 25C, protect from moisture and light.

Drug Class
Proton Pump Inhibitor (Rabeprazole) and Prokinetic (Domperidone)

RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP Trade Information

Minimum Order Quantity
100 Boxes

Delivery Time
Days

Sample Available
No

Packaging Details
10*10

Main Domestic Market
All India

RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP About

Introducing our celebrated RABEPRAZOLE 20M DOMPERIDONE 30MG Sustained Release Capsules, now available at a sizzling price cut! Harness the marvelous power of Rabeprazole, a potent proton pump inhibitor, combined with the resplendent efficacy of Domperidone for dynamic relief from acid reflux, peptic ulcers, and chronic gastritis. Each capsule delivers exacting sustained release, ensuring continuous therapeutic impact. Strictly store below 25C, shielded from moisture and light. With a generous 24-month shelf life and superior packaging for export and domestic users, this prescription capsule is the trusted choice for comprehensive gastrointestinal care.

Comprehensive Uses of RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP

Used as an advanced solution for gastroesophageal reflux disease (GERD), this capsule marvelously addresses acidity and vomiting while providing relief in peptic ulcers and chronic gastritis. Its sustained release formulation allows both general and specific use, making it invaluable for chronic gastrointestinal disorders. Clinicians often prescribe it for varied digestive disturbances, ensuring broad-spectrum effectiveness and targeted relief in persistent gastric ailments.

Certifications, Delivery and Export Market Details

RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP is manufactured under acclaimed quality certifications, meeting stringent pharmaceutical standards. Efficient packaging in 10x10 capsule strips ensures safety and efficacy during nationwide distribution and export delivery. Our celebrated product is extensively supplied across the main domestic market of India and is well-positioned for the international export market. Timely deliveries and secure packaging underscore our commitment to excellence in pharmaceutical trade.

FAQ's of RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP:

Q: How should RABEPRAZOLE 20M DOMPERIDONE 30MG SUS RELEASE CAP be stored for optimal efficacy?

A: It should be stored below 25C, protected from moisture and light, to maintain its efficacy throughout its 24-month shelf life.

Q: What conditions does this capsule effectively treat?

A: It is indicated for gastrointestinal disorders such as acid reflux, peptic ulcer, chronic gastritis, GERD, and related symptoms like acidity and vomiting.

Q: When is the ideal time to administer this medication?

A: This prescription capsule is intended for oral administration, typically before meals to maximize absorption and therapeutic effect. Always follow your physician's guidance regarding timing.

Q: Where is this product primarily distributed and exported?

A: The product is widely distributed across India and exported to various international markets, with adherence to high-quality packaging and delivery standards.

Q: What are the main advantages of the sustained release formulation?

A: The sustained release formulation ensures a controlled and continuous release of active ingredients, providing longer-lasting symptom relief and enhanced patient compliance.